Compare EHang Holdings Ltd - ADR (EH) vs Royalty Pharma plc Class A Ordinary Shares (RPRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EHang Holdings Ltd - ADR vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? EHang Holdings Ltd - ADR trades at $4.2 (market cap $309.45M), while Royalty Pharma plc Class A Ordinary Shares trades at $56.69 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 81.7× EHang Holdings Ltd - ADR's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while EHang Holdings Ltd - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold EHang Holdings Ltd - ADR for 46 Days and Royalty Pharma plc Class A Ordinary Shares for 0 Days on average.
| EH | RPRX | |
|---|---|---|
Market Cap | $309.45M | $25.27B |
Volume | 765,799 | 3,671,183 |
Sector | Industrials | Health |
52-Week High | $18.94 | $63.96 |
52-Week Low | $4.03 | $35.44 |
Typical Hold Time | 46 Days | 0 Days |
Enterprise Value | $261.14M | $32.50B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EHang Holdings (EH) trades at $4.085, down 1.33% on the day, reflecting a bearish technical signal. The company shows a mixed fundamental picture with revenue of $418 million in 2025 but a net loss of $276 million, resulting in a net margin of -66.03%. Recent news includes ongoing legal investigations and expansion of its Global Fast Track Program to Vietnam. Cash flow trends are volatile, with a net cash outflow of $354 million in 2025 despite a strong cash position of $1.12 billion in 2024.
The outlook for EH is highly speculative, with significant execution and regulatory risks overshadowing its pioneering role in the eVTOL sector. While analyst consensus is divided (20% Buy, 40% Hold, 40% Sell), the stock's high volatility and negative profitability metrics suggest caution. Investment opportunity hinges on successful commercialization and regulatory approvals, but current financials and legal headwinds present substantial downside risks.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EHang Holdings Ltd - ADR
EHang Holdings Ltd is an autonomous aerial vehicle (AAV) technology platform company. It focuses on making safe, autonomous and eco-friendly air mobility accessible to everyone. EHang provides customers in various industries with AAV products and commercial solutions: air mobility (including passenger transportation and logistics), smart city management and aerial media solutions. As the forerunner of cutting-edge AAV technologies and commercial solutions in the global Urban Air Mobility industry, it continues to explore the boundaries of the sky to make flying technologies benefit life in smart cities.
Read more on EH →About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →
